نتائج البحث - "Codreanu, Catalin"

المصدر: Pons, Marion; Georgiadis, Stylianos; Østergaard, Mikkel; Ahmadzay, Zohra Faizy; Glintborg, Bente; Heberg, Jette; Christensen, Sara Nysom; Rasmussen, Simon; Loft, Anne Gitte; Castrejon, Isabel; Sánchez-Alonso, Fernando; Iannone, Florenzo; Nordström, Dan; Hokkanen, Anna-Mari; Ciurea, Adrian; Nissen, Michael J; Zavada, Jakub; Pavelka, Karel; Rotar, Ziga; Pirkmajer, Katja Perdan; Michelsen, Brigitte; Mielnik, Pawel; Bernardes, Miguel; Khmelinskii, Nikita; Laas, Karin; Vorobjov, Sigrid; Codreanu, Catalin; Macfarlane, Gary J; Jones, Gareth T; Gudbjornsson, Bjorn; et al (2024). Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine:Epub ahead of print.

مصطلحات موضوعية: Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health

وصف الملف: application/pdf

Relation: https://www.zora.uzh.ch/id/eprint/268131/2/ZORA268131.pdf; info:pmid/39608666; urn:issn:1297-319X

الاتاحة: https://www.zora.uzh.ch/id/eprint/268131/
https://www.zora.uzh.ch/id/eprint/268131/2/ZORA268131.pdf
https://doi.org/10.1016/j.jbspin.2024.105824

View record in BASE

10

Academic Journal

Metabolic syndrome in gout compared to autoimmune rheumatic diseases

المؤلفون: Popescu, Claudiu, Grigore, Mara, Stentel, Carmen, Codreanu, Catalin

المصدر: Rom J Rheumatol, 33(2), (2024-09-30)

مصطلحات موضوعية: Rheumatology

Relation: https://doi.org/10.37897/RJR.2024.33.2.3; oai:zenodo.org:14036098

الاتاحة: https://doi.org/10.37897/RJR.2024.33.2.3

View record in BASE

11

Academic Journal

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum

مصطلحات موضوعية: General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: Linde , L , Georgiadis , S , Ørnbjerg , L M , Rasmussen , S H , Michelsen , B , Askling , J , Di Giuseppe , D , Wallman , J K , Závada , J , Pavelka , K , Bernardes , M , Matos , C O , Glintborg , B , Loft , A G , Nordström , D , Kuusalo , L , Möller , B , Nissen , M J , Codreanu , C , Mogosan , C , Gudbjornsson , B , Love , T J , Akleylek , C , Iannone , F , Kvien , T K , Rotar , Z , Castrejon , I , Macfarlane , G J , Hetland , M L & Østergaard , M 2024 , ' Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries ' , Arthritis Care and Research . https://doi.org/10.1002/acr.25396; http://hdl.handle.net/10138/585130; 60f2dc52-b093-4fd3-b216-01d853054d71; 85201548710; 001294036300001

الاتاحة: http://hdl.handle.net/10138/585130

View record in BASE

12

Academic Journal

Data from the Romanian Registry of Rheumatic Diseases for patients with psoriatic arthritis treated with biologic and targeted-synthetic disease-modifying anti-rheumatic drugs – 2023 update

المؤلفون: BALANESCU, ANDRA RODICA, PÂRVU, MAGDA, MOGOȘAN, CORINA, POPESCU, DANIELA NICOLETA, AVRAM, CLAUDIU, IONIȚESCU, RĂZVAN, DAMIAN, LAURA OTILIA, MARTIN, ANDREI, CODREANU, CĂTĂLIN

المصدر: Rom J Rheumatol, 33(1), (2024-03-31)

مصطلحات موضوعية: Rheumatology

Relation: https://doi.org/10.37897/RJR.2024.33.1.1; oai:zenodo.org:12795440

الاتاحة: https://doi.org/10.37897/RJR.2024.33.1.1

View record in BASE

13

Academic Journal

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

المصدر: Ørnbjerg , L M , Brahe , C H , Linde , L , Jacobsson , L , Nissen , M J , Kristianslund , E K , Santos , M J , Nordström , D , Rotar , Z , Gudbjornsson , B , Onen , F , Codreanu , C , Lindström , U , Möller , B , Kvien , T K , Barcelos , A , Eklund , K K , Tomšič , M , Love , T J , Can , G , Ionescu , R , Loft , A G , Mann , ....

الاتاحة: https://research.vumc.nl/en/publications/74b6bbf4-be89-47e2-b6e6-04dd38b92bf9
https://doi.org/10.1016/j.jbspin.2024.105729
http://www.scopus.com/inward/record.url?scp=85190446423&partnerID=8YFLogxK

View record in BASE

14

Academic Journal

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis

المساهمون: HUS Inflammation Center, Reumatologian yksikkö

مصطلحات موضوعية: spondylitis, ankylosing, MTX, SSZ, TNF inhibitors, epidemiology, MODIFYING ANTIRHEUMATIC DRUGS, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, PSORIATIC-ARTHRITIS, TREATMENT RESPONSE, SPONDYLOARTHRITIS, COMEDICATION, INFLIXIMAB, METHOTREXATE, SURVIVAL, General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit.; Nissen , M , Delcoigne , B , Di Giuseppe , D , Jacobsson , L , Hetland , M L , Ciurea , A , Nekvindova , L , Iannone , F , Akkoc , N , Sokka-Isler , T , Fagerli , K M , Santos , M J , Codreanu , C , Pombo-Suarez , M , Rotar , Z , Gudbjornsson , B , Van der Horst-Bruinsma , I , Loft , A G , Moeller , B , Mann , H , Conti , F , Cetin , G Y , Relas , H , Michelsen , B , Ribeiro , P A , Ionescu , R , Sanchez-Piedra , C , Tomsic , M , Geirsson , A J , Askling , J , Glintborg , B & Lindström , U 2022 , ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis ' , Rheumatology , vol. 61 , no. 12 , pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174; http://hdl.handle.net/10138/575581; c92939b4-34dd-46c0-82a7-b041631b3870; 000784112300001

الاتاحة: http://hdl.handle.net/10138/575581

View record in BASE

15

Academic Journal

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)

المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum

مصطلحات موضوعية: Antirheumatic Agents, Arthritis, Rheumatoid, Biological Therapy, Epidemiology, General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: The JAK-pot study has received unrestricted research grant from: AbbVie, Galapagos, Pfizer and Eli Lilly. BIOREG, the Austrian registry for biologicals, biosimilars and tsDMARDs in the treatment of inflammatory rheumatic diseases, is in close partnership with the Austrian Society for Rheumatology and Rehabilitation (OGR) and is supported by an unrestricted educational grant from AbbVie, Amgen, Eli Lilly, Fresenius-Kabi, Gilead, Janssen-Cilag, MSD, Pfizer, Sandoz, UCB. Clinical work in Czech Republic was partially supported by the project from the Ministry of Health for conceptual development of research organisation MZ00023728023728 (Institute of Rheumatology). BIOBADASER has received funding from Fundacion Espanola de Reumatologia, the Spanish Medicines and Health Products Agency (Agencia Espanola del Medicamento y Productos Sanitarios) and equal grants from pharmaceutical companies (AbbVie, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Samsung, Schering-Plough and UCB). BioRx. si has received funding for clinical research paid to Drustvo za razvoj revmatologije from AbbVie, Roche, Medis, MSD, Biogen, Amgen, Sanofi, Celgene and Pfizer. The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) is funded by a grant from the British Society for Rheumatology (BSR). The BSR currently receives funding from AbbVie, Amgen, Celltrion Healthcare, Eli Lilly, Galapagos, Pfizer, Samsung Bioepis and Sanofi and in the past Hospira, MSD, Roche, Sandoz, SOBI and UCB. This income finances a wholly separate contract between the BSR and The University of Manchester to host the BSRBR-RA. All decisions concerning study design, data capture, analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the BSRBR-RA University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious adverse events outlined in the manuscript have been reported to the appropriate pharmaceutical company as per the contractual agreements/ standard operating procedures. DANBIO was partially supported by public and private funding (AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB). NOR-DMARD has been supported with research funding to Diakonhjemmet Hospital from AbbVie, Amgen, BMS, MSD, Novartis, Pfizer and UCB. The German RABBIT registry is currently supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Samsung Bioepis, Sanofi Aventis, VIATRIS SANTE and UCB, and previously by Roche. REUMA. PT is supported by unrestricted grants from AbbVie, Biogen, Celgene, MSD, Roche, Sanofi and Pfizer. ROB-FIN is funded by AbbVie, Hospira, BMS, MSD, Pfizer, Roche and UCB. The Romanian Registry of Rheumatic Diseases (RRBR) uses unrestricted grants from AbbVie, Pfizer, Eli Lilly, Ewopharma, Nopvartis MSD, Roche, UCB, and BMS. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database is sponsored by public and industrial support (http://scqm.ch/en/ sponsoren/).; Aymon , R , Mongin , D , Bergstra , S A , Choquette , D , Codreanu , C , De Cock , D , Dreyer , L , Elkayam , O , Huschek , D , Hyrich , K L , Iannone , F , Inanc , N , Kearsley-Fleet , L , Koca , S S , Kvien , T K , Leeb , B F , Lukina , G , Nordström , D C , Pavelka , K , Pombo-Suarez , M , Rodrigues , A , Rotar , Z , Strangfeld , A , Verschueren , P , Westermann , R , Zavada , J , Courvoisier , D S , Finckh , A & Lauper , K 2024 , ' Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study) ' , Annals of the Rheumatic Diseases , vol. 83 , no. 4 , pp. 421-428 . https://doi.org/10.1136/ard-2023-224670; http://hdl.handle.net/10138/574261; aef68eeb-ba11-470f-b986-628e05a21385; 001119185000001

الاتاحة: http://hdl.handle.net/10138/574261

View record in BASE

16

Academic Journal

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the â€˜JAK-potâ€™ study)

المصدر: ISSN: 0003-4967 ; Annals of the rheumatic diseases, vol. 83, no. 4 (2024) p. 421-428.

Relation: info:eu-repo/semantics/altIdentifier/pmid/38071508; https://archive-ouverte.unige.ch/unige:178520; unige:178520

الاتاحة: https://archive-ouverte.unige.ch/unige:178520

View record in BASE

17

Academic Journal

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - does it depend on the reason for withdrawal from the previous treatment?

المصدر: Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Linde, Louise; Jacobsson, Lennart; Nissen, Michael J; Kristianslund, Eirik Klami; Santos, Maria José; Nordström, Dan; Rotar, Ziga; Gudbjornsson, Bjorn; Onen, Fatos; Codreanu, Catalin; Lindström, Ulf; Möller, Burkhard; Kvien, Tore K; Barcelos, Anabela; Eklund, Kari K; Tom, Matija; Love, Thorvardur Jon; Can, Gercek; . (2024). Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - does it depend on the reason for withdrawal from the previous treatment? (In Press). Joint bone spine, 91(4), p. 105729. Elsevier 10.1016/j.jbspin.2024.105729

مصطلحات موضوعية: 610 Medicine & health

وصف الملف: application/pdf

Relation: https://boris.unibe.ch/195729/

الاتاحة: https://boris.unibe.ch/195729/1/1-s2.0-S1297319X2400040X-main.pdf
https://boris.unibe.ch/195729/

View record in BASE